Publications by authors named "Kathryn K Erickson-Ridout"
Article Synopsis
- The study investigates the impact of app-enhanced treatment for eating disorders (ED) on clinical outcomes and health care usage in patients receiving outpatient and intensive care.
- Results indicate that patients using the app experienced fewer emergency department visits and increased use of outpatient services, alongside notable weight gain among those who were underweight.
- The findings suggest that integrating digital health tools into ED treatment may improve patient engagement and health results, highlighting the need for further research on long-term benefits and cost-effectiveness.
Introduction: Clozapine (CLZ) is an FDA approved second-generation antipsychotic for refractory schizophrenia, and glucuronidation is an important pathway in its metabolism. The aim of this study was to fully characterize the CLZ glucuronidation pathway and examine whether polymorphisms in active glucuronidating enzymes could contribute to variability in CLZ metabolism.
Methods: Cell lines overexpressing wild-type or variant uridine diphosphate-glucuronosyltransferase (UGT) enzymes were used to determine which UGTs show activity against CLZ and its major active metabolite N-desmethylclozapine (dmCLZ).
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
Pharmacogenet Genomics
September 2011
Objectives: Olanzapine is an antipsychotic used in the treatment of schizophrenia, bipolar disorder, and treatment-resistant depression. Glucuronidation by the UDP-glucuronosyltransferase (UGT) family of enzymes is the major mode of olanzapine metabolism, and polymorphisms in these enzymes could contribute to interindividual variability in olanzapine metabolism and therapeutic response.
Methods: Cell lines overexpressing individual UGT enzymes were used to determine which UGTs have enzymatic activity against olanzapine, characterize the kinetics of this reaction, and examine the effects of UGT variants on olanzapine metabolism.